Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 110

Similar articles for PubMed (Select 20621693)

1.

Complement activation on platelets: implications for vascular inflammation and thrombosis.

Peerschke EI, Yin W, Ghebrehiwet B.

Mol Immunol. 2010 Aug;47(13):2170-5. doi: 10.1016/j.molimm.2010.05.009. Epub 2010 Jun 1. Review.

2.

Serum complement activation on heterologous platelets is associated with arterial thrombosis in patients with systemic lupus erythematosus and antiphospholipid antibodies.

Peerschke EI, Yin W, Alpert DR, Roubey RA, Salmon JE, Ghebrehiwet B.

Lupus. 2009 May;18(6):530-8. doi: 10.1177/0961203308099974.

3.

Blood platelets activate the classical pathway of human complement.

Peerschke EI, Yin W, Grigg SE, Ghebrehiwet B.

J Thromb Haemost. 2006 Sep;4(9):2035-42.

PMID:
16961611
4.

Complement activation in platelet concentrates is surface-dependent and modulated by the platelets.

Gyongyossy-Issa MI, McLeod E, Devine DV.

J Lab Clin Med. 1994 Jun;123(6):859-68.

PMID:
8201264
5.

Platelet activation leads to activation and propagation of the complement system.

Del Conde I, Crúz MA, Zhang H, López JA, Afshar-Kharghan V.

J Exp Med. 2005 Mar 21;201(6):871-9.

6.

Complement activation on platelets correlates with a decrease in circulating immature platelets in patients with immune thrombocytopenic purpura.

Peerschke EI, Andemariam B, Yin W, Bussel JB.

Br J Haematol. 2010 Feb;148(4):638-45. doi: 10.1111/j.1365-2141.2009.07995.x. Epub 2009 Nov 19.

PMID:
19925495
7.

Increased C1q, C4 and C3 deposition on platelets in patients with systemic lupus erythematosus--a possible link to venous thrombosis?

Lood C, Eriksson S, Gullstrand B, Jönsen A, Sturfelt G, Truedsson L, Bengtsson AA.

Lupus. 2012 Nov;21(13):1423-32. doi: 10.1177/0961203312457210. Epub 2012 Aug 9.

PMID:
22878256
8.

New targeted therapies for treatment of thrombosis in antiphospholipid syndrome.

Pierangeli SS, Vega-Ostertag ME, González EB.

Expert Rev Mol Med. 2007 Nov 13;9(30):1-15. Review.

PMID:
17997880
9.

Expression of complement components and inhibitors on platelet microparticles.

Yin W, Ghebrehiwet B, Peerschke EI.

Platelets. 2008 May;19(3):225-33. doi: 10.1080/09537100701777311.

10.

Role of C3 cleavage in monocyte activation during extracorporeal circulation.

Rinder CS, Rinder HM, Johnson K, Smith M, Lee DL, Tracey J, Polack G, Higgins P, Yeh CG, Smith BR.

Circulation. 1999 Aug 3;100(5):553-8.

11.
12.

Autoantibody-mediated complement activation on platelets is a common finding in patients with immune thrombocytopenic purpura (ITP).

Najaoui A, Bakchoul T, Stoy J, Bein G, Rummel MJ, Santoso S, Sachs UJ.

Eur J Haematol. 2012 Feb;88(2):167-74. doi: 10.1111/j.1600-0609.2011.01718.x. Epub 2011 Nov 22.

PMID:
21985182
14.

Increased platelet deposition on extracellular matrix under flow conditions in patients with antiphospholipid syndrome who experience thrombotic events.

Levy Y, Shenkman B, Tamarin I, Pauzner R, Shoenfeld Y, Langevitz P, Savion N, Varon D.

Arthritis Rheum. 2005 Dec;52(12):4011-7.

15.

Platelets, complement, and contact activation: partners in inflammation and thrombosis.

Hamad OA, Bäck J, Nilsson PH, Nilsson B, Ekdahl KN.

Adv Exp Med Biol. 2012;946:185-205. doi: 10.1007/978-1-4614-0106-3_11. Review.

PMID:
21948369
16.

The role of complement in the antiphospholipid syndrome: a novel mechanism for pregnancy morbidity.

Samarkos M, Mylona E, Kapsimali V.

Semin Arthritis Rheum. 2012 Aug;42(1):66-9. doi: 10.1016/j.semarthrit.2012.01.001. Epub 2012 Mar 8. Review.

PMID:
22405029
17.

Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation.

Rinder CS, Rinder HM, Smith BR, Fitch JC, Smith MJ, Tracey JB, Matis LA, Squinto SP, Rollins SA.

J Clin Invest. 1995 Sep;96(3):1564-72.

18.

Complement activation during systemic lupus erythematosus. C3a and C5a anaphylatoxins circulate during exacerbations of disease.

Belmont HM, Hopkins P, Edelson HS, Kaplan HB, Ludewig R, Weissmann G, Abramson S.

Arthritis Rheum. 1986 Sep;29(9):1085-9.

PMID:
3489467
20.

Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis.

Morigi M, Galbusera M, Gastoldi S, Locatelli M, Buelli S, Pezzotta A, Pagani C, Noris M, Gobbi M, Stravalaci M, Rottoli D, Tedesco F, Remuzzi G, Zoja C.

J Immunol. 2011 Jul 1;187(1):172-80. doi: 10.4049/jimmunol.1100491. Epub 2011 Jun 3.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk